Charles Schwab Investment Management Inc Prothena Corp Public LTD CO Transaction History

Charles Schwab Investment Management Inc

$515 Billion
Q3 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 324,962 shares of PRTA stock, worth $4.95 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

324,962

Previous 327,139 0.67%

Holding current value

$4.95 Million

Previous $6.75 Million 19.49%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$16.73 - $24.79 $36,421 - $53,967	-2,177 Reduced 0.67%	324,962 $5.44 Million
Q2 2024 Aug 12, 2024	BUY	$19.54 - $26.15 $160,892 - $215,319	8,234 Added 2.58%	327,139 $6.75 Million
Q1 2024 May 08, 2024	BUY	$24.75 - $40.66 $140,456 - $230,745	5,675 Added 1.81%	318,905 $7.9 Million
Q4 2023 Feb 06, 2024	BUY	$32.31 - $52.32 $151,630 - $245,537	4,693 Added 1.52%	313,230 $11.4 Million
Q3 2023 Nov 08, 2023	SELL	$47.3 - $70.6 $186,645 - $278,587	-3,946 Reduced 1.26%	308,537 $14.9 Million
Q2 2023 Aug 09, 2023	BUY	$48.26 - $78.59 $652,089 - $1.06 Million	13,512 Added 4.52%	312,483 $21.3 Million
Q1 2023 May 11, 2023	SELL	$46.97 - $58.27 $88,256 - $109,489	-1,879 Reduced 0.62%	298,971 $14.5 Million
Q4 2022 Feb 13, 2023	BUY	$52.05 - $65.0 $786,371 - $982,020	15,108 Added 5.29%	300,850 $18.1 Million
Q3 2022 Nov 14, 2022	BUY	$25.16 - $60.63 $207,997 - $501,228	8,267 Added 2.98%	285,742 $17.3 Million
Q2 2022 Aug 15, 2022	SELL	$22.73 - $39.98 $157,450 - $276,941	-6,927 Reduced 2.44%	277,475 $7.53 Million
Q1 2022 May 13, 2022	BUY	$30.27 - $49.22 $871,412 - $1.42 Million	28,788 Added 11.26%	284,402 $10.4 Million
Q4 2021 Feb 11, 2022	BUY	$42.11 - $73.26 $585,286 - $1.02 Million	13,899 Added 5.75%	255,614 $12.6 Million
Q3 2021 Nov 16, 2021	BUY	$48.2 - $78.89 $1.68 Million - $2.75 Million	34,889 Added 16.87%	241,715 $17.2 Million
Q2 2021 Aug 16, 2021	BUY	$21.63 - $57.65 $442,009 - $1.18 Million	20,435 Added 10.96%	206,826 $10.6 Million
Q1 2021 May 17, 2021	BUY	$11.0 - $28.24 $42,372 - $108,780	3,852 Added 2.11%	186,391 $4.68 Million
Q4 2020 Feb 16, 2021	SELL	$10.12 - $13.94 $4,270 - $5,882	-422 Reduced 0.23%	182,539 $2.19 Million
Q3 2020 Nov 13, 2020	SELL	$9.93 - $13.47 $542,446 - $735,825	-54,627 Reduced 22.99%	182,961 $1.83 Million
Q2 2020 Aug 14, 2020	SELL	$9.56 - $12.51 $46,060 - $60,273	-4,818 Reduced 1.99%	237,588 $2.49 Million
Q1 2020 May 15, 2020	BUY	$7.54 - $15.77 $25,636 - $53,618	3,400 Added 1.42%	242,406 $2.59 Million
Q4 2019 Feb 07, 2020	BUY	$7.48 - $17.01 $40,317 - $91,683	5,390 Added 2.31%	239,006 $3.78 Million
Q3 2019 Nov 08, 2019	SELL	$6.89 - $10.45 $4,988 - $7,565	-724 Reduced 0.31%	233,616 $1.83 Million
Q2 2019 Aug 09, 2019	BUY	$8.85 - $12.49 $135,413 - $191,109	15,301 Added 6.99%	234,340 $2.48 Million
Q1 2019 May 14, 2019	SELL	$10.32 - $14.49 $12,693 - $17,822	-1,230 Reduced 0.56%	219,039 $2.66 Million
Q4 2018 Feb 14, 2019	BUY	$8.73 - $13.74 $164,813 - $259,397	18,879 Added 9.37%	220,269 $2.27 Million
Q3 2018 Nov 13, 2018	SELL	$12.7 - $15.79 $43,141 - $53,638	-3,397 Reduced 1.66%	201,390 $2.64 Million
Q2 2018 Aug 08, 2018	BUY	$10.99 - $44.21 $324,567 - $1.31 Million	29,533 Added 16.85%	204,787 $2.99 Million
Q1 2018 May 07, 2018	SELL	$27.95 - $45.04 $185,168 - $298,390	-6,625 Reduced 3.64%	175,254 $6.43 Million
Q4 2017 Jan 17, 2018	BUY	$35.44 - $63.76 $329,627 - $593,031	9,301 Added 5.39%	181,879 $6.82 Million
Q3 2017 Nov 13, 2017	BUY	$53.83 - $67.75 $9.29 Million - $11.7 Million	172,578	172,578 $11.2 Million

Others Institutions Holding PRTA

# of Institutions

184

Shares Held

42.7M

Call Options Held

162K

Put Options Held

102K

View Full List

About PROTHENA CORP PUBLIC LTD CO

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $714M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

More about PRTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Prothena Corp Public LTD CO Transaction History